Apellis Patent-Cliff Exposure & CMS Drug Spending Portfolio
Apellis (US): 2 reconciled FDA prescription therapies, $39.2M 2024 CMS Part D & Medicaid spend, and $2,256 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 2 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2038-01-01 |
| 2024 CMS Total Public Spend | $39.2M |
| 2024 Medicare Part D Spend | $28.6M |
| 2024 Medicaid Spend | $10.7M |
| California HCAI SB 17 Filings | Specialty launch notice ($2,256 intro WAC) |